Amendments to the Claims:

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claims 1-20 Cancelled

- 21. (Amended) A method for assaying a compound or combination of compounds capable of inhibiting Human Immunodeficiency Virus ("HIV") entry into a cell comprising:
 - a. co-cultivating a first cell line expressing a gp120-gp41 complex on its cell surface and comprising an inducer, and a second cell line expressing CD4 and CXCR4 its co receptors on its cell surface and comprising a reporter gene, the expression of which is induced by the inducer of the first cell line, in the presence of a compound or combination of compounds under conditions that allow cell fusion;
 - b. comparing the level of expression of the reporter gene in the presence of said compound(s) with the level of expression of the reporter gene in the absence of said compound(s).
- 22. (Previously Presented) The method of claim 21, wherein the inducer is a Tat protein.
- 23. (Previously Presented) The method of claim 21, wherein the reporter gene is beta-galactosidase.
- 24. (Previously Presented) The method of claim 21, wherein the first cell line is HL2/3 cell line.

NYI-4080683vI - 2 -

- 25. (Previously Presented) The method of claim 21, wherein the second cell line is a HeLa-CD4-LTR-β-gal or U373-MAGI-CXCR4.
- 26. (Previously Presented) The method of claim 21, wherein the compound or combination of compounds to be tested is added at varying concentrations.
- 27. (Previously Presented) A method for assaying for a synergistic combination of compounds capable of inhibiting Human Immunodeficiency Virus ("HIV") entry into a cell comprising:
 - a. co-cultivating a first cell line expressing a gp120-gp41 complex on its cell surface and comprising an inducer, and a second cell line expressing CD4 and its co-receptors on its cell surface and comprising a reporter gene, the expression of which is induced by the inducer of the first cell line,
 - i. in the presence of a combination of compounds;
 - ii. in the presence of each individual compound of the combination alone;
 and
 - iii. in the absence of any compound; and
 - b. comparing the level of expression of the reporter gene for each of (i), (ii), and (iii),

wherein a combination of compounds is synergistic if the level of expression in (i) is less than the additive level of expression for each compound in (ii), as compared to the level of expression in (iii).

- 28. (Previously Presented) The method of claim 27, wherein the inducer is a Tat protein.
- 29. (Previously Presented) The method of claim 27, wherein the reporter gene is beta-galactosidase.

- 30. (Previously Presented) The method of claim 27, wherein the first cell line is HL2/3 cell line.
- 31. (Previously Presented) The method of claim 27, wherein the second cell line is HeLa-CD4-LTR- β -gal or U373-MAGI-CXCR4.
- 32. (Withdrawn) A kit comprising:
 - a. a first cell line first cell line expressing a gp120-gp41 complex on its cell surface and comprising an inducer, and
 - b. a second cell line expressing CD4 and its co-receptors on its cell surface and comprising a reporter gene.
- 33. (Withdrawn) The kit of claim 32, wherein the first cell line is in a container separate from the second cell line.
- 34. (Withdrawn) The kit of claim 32, wherein the first cell line is HL2/3.
- 35. (Withdrawn) The kit of claim 32, wherein the second cell line is HeLa-CD4-LTR- β gal or U373-MAGI-CXCR4.
- 36. (Withdrawn) The kit of claim 32, further comprising one or more plates comprising wells.
- 37. (Withdrawn) The kit of claim 32, further comprising a cell lysis buffer.
- 38. (Withdrawn) The kit of claim 32, further comprising a substrate for reporter gene expression detection.
- 39. (Withdrawn) The kit of claim 38, wherein the substrate comprises a chemiluminescent compound.

- 40. (Withdrawn) The kit of claim 32, further comprising a light emission enhancement solution.
- 41. (New) The method of claim 27, wherein the coreceptor is CXCR4.
- 42. (New) The method of claim 27, wherein the coreceptor is CCR5.